Truist analyst Joon Lee initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $16 price target Solid Biosciences, a clinical stage biotech developing gene therapies for diseases of the neuromuscular system, emerged from the merger of two companies, SolidBio and AavantiBio, the analyst tells investors in a research note. The first-in-human look from the ongoing Phase 1/2 study of SGT-003 in Duchenne muscular dystrophy in the first quarter of 2025 could help incrementally de-risk the program and platform as additional Investigational New Drugs are planned for cardiac indications in 1H25, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences initiated with a Buy at Truist
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
- Solid Biosciences gains 12% to $4.40 on FDA clearance of SGT-212 IND
- Solid Biosciences announces FDA clearance of SGT-212 IND application
- Solid Biosciences reports inducement grants under Nasdaq listing rule
Questions or Comments about the article? Write to editor@tipranks.com